2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…2015 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid (MPA) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly (≥60years) recipients are nowadays receiving renal transplants more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include old…2015 American Transplant Congress
New Insights in Clinical and Genetic Determinants of Longitudinal Dose-Corrected CNI Exposure in Children After Renal Transplantation
Purpose: Calcineurin-inhibitors (CNI) have a narrow therapeutic index and dosing is difficult due to inter- and intra-individual variation in pharmacokinetics (PK). Polymorphisms in genes involved…2015 American Transplant Congress
Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression was evaluated in clinical outcomes as well as protocol biopsies findings and donor…2015 American Transplant Congress
Pharmacogenomic Predictors of Acute Rejection in Kidney Transplant Recipients Identified Using a DNA Biobank Linked to Electronic Medical Records
Purpose: Risk for acute rejection (AR) complicating transplant immunosuppression may be affected by frequent variants in pharmacogenes. Using a DNA biobank linked to electronic medical…2015 American Transplant Congress
Influence of POR*28 Genotype on Tacrolimus Disposition in Heart Transplant Recipients
Polymorphisms in P450 oxidoreductase (POR) have been shown to modulate CYP3A activity and alter the pharmacokinetics of CYP3A substrates, such as tacrolimus (TAC). The objective…2015 American Transplant Congress
Opportunities in Tacrolimus Therapeutic Drug Monitoring
Department of Pharmacy, NewYork-Presbyterian Hospital, NY.
Tacrolimus requires diligent therapeutic drug monitoring (TDM) to maintain appropriate serum concentrations after transplant. To optimize efficacy & minimize toxicity frequent levels are drawn, commonly…2015 American Transplant Congress
Prospective, 6 Month, Open Label, Conversion Study from Mycophenolate Mofetyl to Mycophenolic Acid Evaluating the Severity of Gastro-Intestinal Symptoms and Mycophenolic Acid Urinary Metabolite as a Surrogate Marker of Plasmatic Area Under the Curve
Introduction: Treatment with mycophenolate mofetil (MMF) often results in adverse gastro-intestinal (GI) events, which can lead to dose reductions that in turn can increase the…2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…2015 American Transplant Congress
Does Infection Impact On Tacrolimus Blood Levels in Kidney Transplant Recipients?
Background Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy in kidney transplant recipients. It is metabolized by members of the cytochrome p450 (CYP) 3A subfamily…
American Transplant Congress abstracts